Leflunomid (Arava)

Internistische Praxis

Volumn 41, Issue 1, 2001, Pages 155-162

  Miehle, W ^a  

^a BfA Rheumazentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2; CYTOSINE; DIHYDROOROTATE DEHYDROGENASE; DRUG METABOLITE; GUANOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE; PYRIMIDINE NUCLEOTIDE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; TRANSFORMING GROWTH FACTOR BETA; URIDINE; URIDINE PHOSPHATE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PROTEIN BINDING; FIRST PASS EFFECT; HUMAN; LIVER CIRCULATION; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 0035072619     PISSN: 00209570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Rheumatoid Arthritis Section. Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis
2. Medikamentöse Therapie
3. T cells: Pathogenic cells and therapeutic targets in rheumatoid arthritis
4. Mechanism of action of leflunomide in rheumatoid arthritis
5. Leflunomid. Neues Wirkprinzip bei Rheumatoider Arthritis
6. The efficacy of leflunomide (Arava) for the treatment of rheumatoid arthritis
7. Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency
8. Differential effects of the immunosuppressive agents cyclosporine lefluonomide in vivo: Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock
9. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
10. Maintaining genetic stability through a p53 mediated checkpoint control
11. Leflunomide. A review of its use in active rheumatoid arthriti
12. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
13. Effects of leflunomide on early T-cell signalling and cell cycle commitment
14. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest
15. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
16. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicenter trial
17. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
18. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis
19. Function and health-related quality of life
20. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis
21. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
22. Effect of leflunomide and cyclosporine on graft survival and changes in lymphocyte phenotypes in a rat heart allotransplantation model
23. The effects of leflunomide and cyclosporin A on rejection of cardiac allografts in the rat
24. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis
25. The immunosuppressive metabolite of leflunomide, A77 1726, effects murine T cells through two biochemical mechanisms
26. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression
27. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 metalloproteinases
28. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis
29. The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS
30. A novel mechanism of action of the immunomodulatory drug, leflunomide: Augmentation of the immunosuppressive cytokine. TGF-beta 1, and supression of the immunostimulatory cytokine, IL-2
31. P53 dependent apoptosis in the absence of transcriptional activation of p53 target genes
32. Activation induced apoptosis in lymphocytes
33. P53, guardian of the genome
34. Purine nucleotide metabolism in phytohemagglutinin induced human T lymphocytes
35. Roles of tghe tumor suppressor p53 and the cyclin dependent kinase inhibitor p21WAD1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells
36. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound
37. Dihydroorotate dehydrogenase pyramidine nucleotide biosynthesis
38. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
39. Leflunomide inhibits pyrimidine de nove synthesis in mitogen stimulate T-lymphocytes from healthy humans
40. Mechanism of the anti-proliferative action of leflunomide
41. The combination of leflunomide (LEF) and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who are failing on MTX treatment alone: A doubleblind placebo (PLL) controlled study